Adherence to HIV therapeutic drug monitoring guidelines in the Netherlands

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 32-39

  Van Luin, Matthijs ^a,b   Wit, Ferdinand W ^c   Smit, Colette ^d   Rigter, Irma M ^e   Franssen, Eric J F ^b   Richter, Clemens ^b   Kroon, Frank ^f   De Wolf, Frank ^d,g   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Nijmegen Institute for Infection Inflammation and Immunity ^*  (Netherlands)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d STICHTING HIV MONITORING   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

guidelines; HIV; therapeutic drug monitoring

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; BENZOXAZINES; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; NETHERLANDS; NEVIRAPINE; PREGNANCY; PYRIMIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78751644504     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318205b81d     Document Type: Article

References (23)

1. DHHS Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents 2009 (updated December 1, 2009). Available at: http://aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL.pdf. Accessed July 29, 2010.
2. Baxter JD, Merigan TC, Wentworth DN, et al. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS. 2002;16: 1131-1138.
3. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75. (Pubitemid 32055781)
4. Veldkamp AI, Weverling GJ, Lange JMA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
5. Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000; 30(Suppl 2):S151-S159.
6. Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42:599-605.
7. Barry MG, Merry C, Lloyd J, et al. Variability in trough plasma saquinavir concentrations in HIV patients - a case for therapeutic drug monitoring. Br J Clin Pharmacol. 1998;45:501-502.
8. Regazzi MB, Villani P, Maserati R, et al. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol. 1999;47:379-382.
9. Marzolini C, Buclin T, Decosterd LA, et al. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient variability and low intrapatient variability. Therapeutic Drug Monitoring. 2001;23:394-398.
10. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551-560.
11. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
12. Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren. Herziene richtlijn Antiretrovirale Behandeling (updated December 2007). Available at: www.nvab.org Accessed July 29, 2010.
13. Revised guideline 'Antiretroviral Treatment.' Ned Tijdschr Geneeskd. 2005;149:2399-2405.
14. FDA. Kaletra; Prescribing information. Available at: www.accessdata.fda. gov/drugsatfda-docs/label/2007/021226s022lbl.pdf. Accessed July 29, 2010.
15. Nellen JF, Schillevoort I, Wit FW, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis. 2004;39:736-740.
16. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62:309-315.
17. Angel JB, Khaliq Y, Monpetit ML, et al. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. AIDS. 2001;15:417-419.
18. Gras L, Van Sighem AI, Smit C, et al. Monitoring of human immunodeficiency virus (HIV) infection in The Netherlands. Report 2009. Available at: www.hiv-monitoring.nl. Accessed July 29, 2010.
19. Van Luin M, Kuks PF, Burger DM. Use of therapeutic drug monitoring in HIV disease. Curr Opin HIV AIDS. 2008;3:266-271.
20. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr. 2006;41: 461-467.
21. Anonymous. BHIVA Guidelines for the treatment of HIV-infected adults treated with antiretroviral therapy (updated 10 June 2008). Available at: www.bhiva.org/documents/Guidelines/Treatment%20Guidelines/Current/ TreatmentGuidelines2008.pdf. Accessed July 29, 2010.
22. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir- containing regimens. J Acquir Immune Defic Syndr. 2003;33:594-600.
23. Van Luin M, Gras L, Richter C, et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations J Acquir Immune Defic Syndr. 2009;52:240-245.